Literature DB >> 22966292

Human papillomavirus genotypes in penile cancers from Japanese patients and HPV-induced NF-κB activation.

Masachika Senba1, Naoki Mori, Akihiro Wada, Shuichi Fujita, Michio Yasunami, Sumiko Irie, Tomayoshi Hayashi, Tsukasa Igawa, Hiroshi Kanetake, Osamu Takahara, Kan Toriyama.   

Abstract

The causal relationship between chronic inflammation and cancer is widely accepted. Numerous investigations have identified nuclear factor-κB (NF-κB) as an important modulator in driving chronic inflammation to cancer. This study aimed to determine the prevalence of human papillomavirus (HPV) in penile cancer in Japanese patients and whether NF-κB is subsequently overexpressed in penile cancer. Thirty-four specimens of penile tissue (16 malignant and 18 benign cases) were examined to determine the association of HPV infection. An in situ hybridization (ISH) method was used to detect and localize HPV-DNA. A sensitive HPV polymerase chain reaction (PCR) procedure was used for the detection of HPV-DNA, and DNA sequencing was used to identify the HPV genotype. HPV-DNA was detected in 37.5 and 75% of cases of penile cancer, using ISH and PCR, respectively. Our efforts to detect HPV genotypes were unsuccessful as HPV-DNA could not be extracted from these materials. Using ISH, a prevalence of 68.2% of HPV infection was found in penile cancer in Kenyan patients in east Africa. In the present study, all 9 HPV-positive cases, (100%) were NF-κB-positive in the nucleus and/or cytoplasm. In contrast, of the 25 HPV-negative cases, 15 (60%) were NF-κB-positive in the nucleus and/or cytoplasm. Therefore, ISH is a method which is able to prove infection of a large quantity of HPV more effectively when compared with PCR. Thus, a large quantity of HPV infection leads to the activity of NF-κB. The most prevalent genotype was the HPV-22 found in 83.3% of the penile cancer cases. In addition, HPV-11 was found in 81.8% of the non-cancer cases. For cases with a high level of infection, the activity of NF-κB increased compared with those with a low level of HPV infection.

Entities:  

Year:  2010        PMID: 22966292      PMCID: PMC3436415          DOI: 10.3892/ol_00000047

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  27 in total

Review 1.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

2.  Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer.

Authors:  Jennifer S Smith; Rolando Herrero; Cristina Bosetti; Nubia Muñoz; F Xavier Bosch; José Eluf-Neto; Xavier Castellsagué; Chris J L M Meijer; Adriaan J C Van den Brule; Silvia Franceschi; Rhoda Ashley
Journal:  J Natl Cancer Inst       Date:  2002-11-06       Impact factor: 13.506

3.  Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection.

Authors:  Alok Mishra; Alok C Bharti; Prishla Varghese; Daman Saluja; Bhudev C Das
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

4.  The prevalence of human papillomavirus genotypes in penile cancers from northern Thailand.

Authors:  Masachika Senba; Atsushi Kumatori; Shuichi Fujita; Prapan Jutavijittum; Amnat Yousukh; Toshiyuki Moriuchi; Tsuyoshi Nakamura; Kan Toriyama
Journal:  J Med Virol       Date:  2006-10       Impact factor: 2.327

5.  High levels of p105 (NFKB1) and p100 (NFKB2) proteins in HPV16-transformed keratinocytes: role of E6 and E7 oncoproteins.

Authors:  L Havard; S Rahmouni; J Boniver; P Delvenne
Journal:  Virology       Date:  2005-01-20       Impact factor: 3.616

Review 6.  Papillomaviruses in the causation of human cancers - a brief historical account.

Authors:  Harald zur Hausen
Journal:  Virology       Date:  2009-01-08       Impact factor: 3.616

7.  Detection of human papillomavirus in squamous neoplasm of the penis.

Authors:  F H Sarkar; B J Miles; D H Plieth; J D Crissman
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

8.  Human papillomavirus (HPV) DNA in penile carcinomas and in two cell lines from high-incidence areas for genital cancers in Africa.

Authors:  M L Tornesello; F M Buonaguro; E Beth-Giraldo; S K Kyalwazi; G Giraldo
Journal:  Int J Cancer       Date:  1992-06-19       Impact factor: 7.396

9.  Basaloid squamous cell carcinoma: a distinctive human papilloma virus-related penile neoplasm: a report of 20 cases.

Authors:  A L Cubilla; V E Reuter; L Gregoire; G Ayala; S Ocampos; W D Lancaster; W Fair
Journal:  Am J Surg Pathol       Date:  1998-06       Impact factor: 6.394

10.  Detection of Human papillomavirus and cellular regulators p16INK4a, p53, and NF-kappaB in penile cancer cases in Kenya.

Authors:  M Senba; N Buziba; N Mori; A Wada; S Irie; K Toriyama
Journal:  Acta Virol       Date:  2009       Impact factor: 1.162

View more
  4 in total

1.  Human papillomavirus infection induces NF-κB activation in cervical cancer: A comparison with penile cancer.

Authors:  Masachika Senba; Nathan Buziba; Naoki Mori; Shuichi Fujita; Konosuke Morimoto; Akihiro Wada; Kan Toriyama
Journal:  Oncol Lett       Date:  2010-11-23       Impact factor: 2.967

2.  Relationship among human papillomavirus infection, p16(INK4a), p53 and NF-κB activation in penile cancer from northern Thailand.

Authors:  Masachika Senba; Naoki Mori; Shuichi Fujita; Prapan Jutavijittum; Amnat Yousukh; Kan Toriyama; Akihiro Wada
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 3.  Mechanisms of virus immune evasion lead to development from chronic inflammation to cancer formation associated with human papillomavirus infection.

Authors:  Masachika Senba; Naoki Mori
Journal:  Oncol Rev       Date:  2012-10-05

4.  The relationship between human papillomavirus and penile cancer over the past decade: a systematic review and meta-analysis.

Authors:  Yong-Bo Yu; Yong-Hua Wang; Xue-Cheng Yang; Yang Zhao; Mei-Lan Wang; Ye Liang; Hai-Tao Niu
Journal:  Asian J Androl       Date:  2019 Jul-Aug       Impact factor: 3.285

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.